Under the partnership, more than 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies will be used on the COMET platform to quickly develop antibody panels
The end-to-end spatial biology solution portfolio of Lunaphore. (Credit: Lunaphore Technologies SA.)
Swiss life sciences company Lunaphore and US-based Cell Signaling Technology (CST) have entered into a partnership to use the latter’s antibodies on the former’s COMET platform to advance spatial biology research.
The Lunaphore COMET platform is a scalable hyperplex imaging solution for 100% automated spatial biology.
Cell Signaling Technology, which is a life science discovery technology company, supplies antibodies for immunohistochemistry (IHC) to detect key proteins in a range of disease states.
Under the partnership, more than 1,700 IHC-validated antibodies from Cell Signaling Technology detected by fluorescent secondary antibodies will be used on the COMET platform. This will enable researchers to develop antibody panels quickly and with confidence, said the companies.
Researchers relying on Cell Signaling Technology’s antibody products will now have access to tools that can enable fully automated hyperplex imaging at scale along with a primary rabbit and mouse antibodies range.
Cell Signaling Technology antibody applications and validation senior director Katie Crosby said: “As a scientist-led company, we understand the importance of validating antibodies in each application independently. We do not infer performance in IHC based on western blot, for example.
“That’s why our team at CST has rigorously tested every one of our IHC-validated antibodies to ensure their specificity and sensitivity in IHC assays.”
The COMET platform is said to be the first universal, end-to-end spatial biology system. It is designed to evaluate the distribution and abundance of several proteins on a single tissue segment without the use of conjugate primary antibodies.
It can examine cellular systems to find new biological pathways, from early discovery through late-stage translational and clinical research initiatives in fields including immuno-oncology, infectious disease, and neuroscience research.
COMET platform’s full-tissue preservation capabilities enable additional downstream study while its walk-away automation maximises reproducibility.
Lunaphore CMO Déborah Heintze said: “The COMET offers unparalleled flexibility in antibody panel design, and when combined with the comprehensive portfolio of primary antibodies from CST, the research community can confidently generate high-resolution hyperplex images in a matter of days.
“The CST products tested on COMET gave clear results, demonstrating the capability to produce the high-quality images needed to enable the next generation of spatial biology research.”